249 related articles for article (PubMed ID: 32933995)
1. Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
Hopkins AM; Kichenadasse G; Karapetis CS; Rowland A; Sorich MJ
Clin Cancer Res; 2020 Oct; 26(20):5487-5493. PubMed ID: 32933995
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.
Hopkins AM; Kichenadasse G; McKinnon RA; Abuhelwa AY; Logan JM; Badaoui S; Karapetis CS; Rowland A; Sorich MJ
Br J Cancer; 2022 Jan; 126(1):42-47. PubMed ID: 34711947
[TBL] [Abstract][Full Text] [Related]
3. Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
Hopkins AM; Kichenadasse G; Karapetis CS; Rowland A; Sorich MJ
Eur Urol; 2020 Oct; 78(4):540-543. PubMed ID: 32660748
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials.
Hopkins AM; Badaoui S; Kichenadasse G; Karapetis CS; McKinnon RA; Rowland A; Sorich MJ
J Thorac Oncol; 2022 Jun; 17(6):758-767. PubMed ID: 35183773
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
Chalabi M; Cardona A; Nagarkar DR; Dhawahir Scala A; Gandara DR; Rittmeyer A; Albert ML; Powles T; Kok M; Herrera FG;
Ann Oncol; 2020 Apr; 31(4):525-531. PubMed ID: 32115349
[TBL] [Abstract][Full Text] [Related]
6. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
[TBL] [Abstract][Full Text] [Related]
7. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
8. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
JAMA Oncol; 2020 Apr; 6(4):512-518. PubMed ID: 31876896
[TBL] [Abstract][Full Text] [Related]
9. The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy.
Li M; Zeng C; Yao J; Ge Y; An G
Int Immunopharmacol; 2020 Nov; 88():106972. PubMed ID: 33182025
[TBL] [Abstract][Full Text] [Related]
10. Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab.
Kunimitsu Y; Morio K; Hirata S; Yamamoto K; Omura T; Hara T; Harada K; Fujisawa M; Yano I
Biol Pharm Bull; 2022; 45(5):590-595. PubMed ID: 35491164
[TBL] [Abstract][Full Text] [Related]
11. Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma.
Fukuokaya W; Akazawa K; Kimura T
Anticancer Res; 2024 May; 44(5):2117-2123. PubMed ID: 38677745
[TBL] [Abstract][Full Text] [Related]
12. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors.
Baek YH; Kang EJ; Hong S; Park S; Kim JH; Shin JY
Int J Cancer; 2022 Apr; 150(8):1291-1300. PubMed ID: 34877670
[TBL] [Abstract][Full Text] [Related]
14. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
Front Oncol; 2022; 12():753234. PubMed ID: 35280736
[TBL] [Abstract][Full Text] [Related]
15. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
[TBL] [Abstract][Full Text] [Related]
16. Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Chen B; Yang C; Dragomir MP; Chi D; Chen W; Horst D; Calin GA; Li Q
Ther Adv Med Oncol; 2022; 14():17588359221111703. PubMed ID: 35860836
[TBL] [Abstract][Full Text] [Related]
17. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
Front Immunol; 2021; 12():716317. PubMed ID: 34777340
[TBL] [Abstract][Full Text] [Related]
18. Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
Tomisaki I; Harada M; Minato A; Nagata Y; Kimuro R; Higashijima K; Harada K; Fujimoto N
Anticancer Res; 2022 Mar; 42(3):1629-1634. PubMed ID: 35220261
[TBL] [Abstract][Full Text] [Related]
19. The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis.
Chang Y; Lin WY; Chang YC; Huang CH; Tzeng HE; Abdul-Lattif E; Wang TH; Tseng TH; Kang YN; Chi KY
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612290
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies.
Sotelo M; Alonso-Gordoa T; Gajate P; Gallardo E; Morales-Barrera R; Pérez-Gracia JL; Puente J; Sánchez P; Castellano D; Durán I
Clin Transl Oncol; 2021 Apr; 23(4):882-891. PubMed ID: 32897497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
